Article ID Journal Published Year Pages File Type
4001322 Urologic Oncology: Seminars and Original Investigations 2006 5 Pages PDF
Abstract

BackgroundBoth bacillus Calmette-Guérin (BCG) and interferon-alpha (IFN-α) express activity against superficial bladder cancer. The results of a national multicenter phase II trial of a combination of these 2 agents used in a wide range of patients are reported.Materials and MethodsPatients previously having BCG failure received IFN-α (50 million units) plus reduced dose BCG, while patients naïve to BCG received the same IFN-α dose with standard dose BCG. All patients who were relapse free received an additional 3 series of 3-week reduced dose BCG plus IFN-α treatments at 3, 9, and 15 months after completing induction. Any relapse during the 3-month evaluation was counted as a failure of therapy for Kaplan-Meier analysis. Multivariate analysis was performed to identify factors associated with recurrence.ResultsOf 1,007 valuable patients, 59% and 45% of patients naïve to BCG and those having BCG failure, respectively, remained disease free at 24-month median follow-up. Stage T1, tumor size >5 cm, prior BCG failure more than once, and multifocality were all statistically significant risk factors for recurrence.ConclusionsAlthough BCG plus IFN-α can be effectively applied to both patients naïve to BCG and those having BCG failure, certain patient and tumor characteristics influence durable response.

Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , ,